FRATES JAMES M — SEC insider filings

SEC reporting owner CIK 1235598. 34 insider filings on record with FilingPulse; latest filed 2026-11-12.

Transaction summary — filings shown

Covers all 34 filings on record, filed 2021-06-11 to 2026-11-12. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Amylyx Pharmaceuticals, Inc. (AMLX)Chief Financial Officer261 leg · 40,000 sh · $101,36821 legs · 191,722 sh · $5,076,68033
Sage Therapeutics, Inc. (SAGE)Director81 leg · 1,810 sh · $99,735—9

Insider filings — FRATES JAMES M

FiledFormIssuerReported transactionsSource
2026-11-124Amylyx Pharmaceuticals, Inc. (AMLX)Option exercise (M): 20,000 @ $6.88 · Sale (S): 7,700 @ $29.39 · Sale (S): 12,300 @ $30.11 · Option exercise (M): 20,000 @ $6.88 · Sale (S): 12,800 @ $30.32 · Sale (S): 7,200 @ $30.97 · +2 moreEDGAR
2026-09-144Amylyx Pharmaceuticals, Inc. (AMLX)Sale (S): 9,768 @ $32.27 · Sale (S): 1,042 @ $33.23EDGAR
2026-08-204Amylyx Pharmaceuticals, Inc. (AMLX)Grant/award (A): 22,807 @ $0EDGAR
2026-03-094Amylyx Pharmaceuticals, Inc. (AMLX)Grant/award (A): 95,990 @ $0 · Grant/award (A): 143,985 (derivative) @ $0EDGAR
2026-03-044Amylyx Pharmaceuticals, Inc. (AMLX)Sale (S): 7,909 @ $14.52EDGAR
2026-02-044Amylyx Pharmaceuticals, Inc. (AMLX)Sale (S): 3,557 @ $14.65EDGAR
2026-01-084Amylyx Pharmaceuticals, Inc. (AMLX)Sale (S): 3,326 @ $11.11EDGAR
2025-10-024Amylyx Pharmaceuticals, Inc. (AMLX)Sale (S): 10,558 @ $14.65EDGAR
2025-07-314Sage Therapeutics, Inc. (SAGE)Code (U): 2,845 · Disposition to issuer (D): 19,154 (derivative) · Disposition to issuer (D): 21,500 (derivative)EDGAR
2025-06-134Sage Therapeutics, Inc. (SAGE)Grant/award (A): 21,500 (derivative) @ $0EDGAR
2025-04-024Amylyx Pharmaceuticals, Inc. (AMLX)Sale (S): 10,896 @ $3.47EDGAR
2025-03-104Amylyx Pharmaceuticals, Inc. (AMLX)Grant/award (A): 68,420 @ $0 · Grant/award (A): 102,630 (derivative) @ $0EDGAR
2024-09-164Amylyx Pharmaceuticals, Inc. (AMLX)Purchase (P): 40,000 @ $2.53EDGAR
2024-09-054/AAmylyx Pharmaceuticals, Inc. (AMLX)Option exercise (M): 18,165 @ $6.88 · Option exercise (M): 18,165 (derivative) @ $0EDGAR
2024-06-114Sage Therapeutics, Inc. (SAGE)Grant/award (A): 12,500 (derivative) @ $0EDGAR
2024-04-184Amylyx Pharmaceuticals, Inc. (AMLX)Grant/award (A): 91,180 @ $0 · Grant/award (A): 120,000 (derivative) @ $0EDGAR
2024-03-074Amylyx Pharmaceuticals, Inc. (AMLX)Sale (S): 1,792 @ $18.73EDGAR
2024-02-284Amylyx Pharmaceuticals, Inc. (AMLX)Grant/award (A): 40,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0EDGAR
2024-01-114Amylyx Pharmaceuticals, Inc. (AMLX)Sale (S): 2,716 @ $16.33EDGAR
2024-01-044Sage Therapeutics, Inc. (SAGE)Grant/award (A): 4,925 (derivative) @ $0EDGAR
2023-11-024Amylyx Pharmaceuticals, Inc. (AMLX)Gift (G): 11,072 @ $0EDGAR
2023-08-244Amylyx Pharmaceuticals, Inc. (AMLX)Option exercise (M): 18,165 @ $6.88 · Option exercise (M): 18,165 (derivative) @ $0EDGAR
2023-06-164Sage Therapeutics, Inc. (SAGE)Grant/award (A): 10,000 (derivative) @ $0EDGAR
2023-05-184Amylyx Pharmaceuticals, Inc. (AMLX)Option exercise (M): 32,500 @ $6.88 · Sale (S): 32,000 @ $26.93 · Sale (S): 500 @ $27.60 · Option exercise (M): 32,500 (derivative) @ $0EDGAR
2023-04-264/AAmylyx Pharmaceuticals, Inc. (AMLX)Conversion (C): 19,482 @ $0 · Conversion (C): 19,482 (derivative) @ $0EDGAR
2023-03-244/AAmylyx Pharmaceuticals, Inc. (AMLX)Option exercise (M): 32,500 @ $6.88 · Sale (S): 30,796 @ $31.86 · Sale (S): 1,704 @ $32.46 · Grant/award (A): 21,667 @ $0 · Grant/award (A): 97,500 (derivative) @ $0 · Option exercise (M): 32,500 (derivative) @ $0EDGAR
2023-03-204Amylyx Pharmaceuticals, Inc. (AMLX)Sale (S): 30,796 @ $31.86 · Sale (S): 1,704 @ $32.46 · Grant/award (A): 21,667 @ $0 · Grant/award (A): 97,500 (derivative) @ $0EDGAR
2023-01-104Amylyx Pharmaceuticals, Inc. (AMLX)Sale (S): 1,836 @ $36.08 · Sale (S): 822 @ $36.79EDGAR
2023-01-044Amylyx Pharmaceuticals, Inc. (AMLX)Option exercise (M): 5,000 @ $6.88 · Option exercise (M): 5,000 (derivative) @ $0EDGAR
2022-06-174Sage Therapeutics, Inc. (SAGE)Grant/award (A): 9,947 (derivative) @ $0EDGAR
2022-03-284Amylyx Pharmaceuticals, Inc. (AMLX)Grant/award (A): 25,000 (derivative) @ $0EDGAR
2022-01-104Amylyx Pharmaceuticals, Inc. (AMLX)Grant/award (A): 31,667 @ $0 · Grant/award (A): 142,500 (derivative) @ $0EDGAR
2021-06-174Sage Therapeutics, Inc. (SAGE)Purchase (P): 1,810 @ $55.10EDGAR
2021-06-114Sage Therapeutics, Inc. (SAGE)Grant/award (A): 10,000 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-11-20 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1235598 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs